For this, we expressed the cancer patient-derived mutants E180K, R181L, R181H, R181C, R181P, and the engineered mutant E180R in comparison to WT, the R175H hotspot mutant, and GFP as a negative control in p53-deficient Saos-2 osteosarcoma cells. This evidence concerns the gene TP53 and cancer.